Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TiGenix

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

More Brexit chaos as government suffers more defeats

UK parliament rejects a no-deal Brexit

- PMLiVE

Takeda’s Entyvio tops Humira in ulcerative colitis

Entyvio is important for post-merger Takeda

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

Medicines will take priority over food in no-deal Brexit

The UK is more reliant on the EU for medicines than food, says Hancock

- PMLiVE

Vertex gains EU approval for earlier Orkambi use

Cystic Fibrosis drug approved in children aged 2-5 years

- PMLiVE

Crunch time as Brexit deal faces ‘meaningful vote’

Rejecting the deal would either result in a no deal or no Brexit, warns May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links